Aims/hypothesis We examined the effects of serum insulin levels on vagal control over the heart and tested the hypothesis that higher fasting insulin levels are associated with lower vagal control. We also examined whether experimentally induced increases in insulin by beta cell secretagogues, including glucagon-like peptide-1 (GLP-1), will decrease vagal control. Methods Respiration and ECGs were recorded for 130 healthy participants undergoing clamps. Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart-rate variability [HRV] caused by peakvalley respiratory sinus arrhythmia [pvRSA], and highfrequency power [HF]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of insulin (achieved by administering insulin plus glucose, glucose only, glucose and GLP-1, and glucose and GLP-1 combined with arginine). Results Serum insulin level was positively associated with HR at all time points during the clamps except the firstphase hyperglycaemic clamp. Insulin levels were negatively correlated with variables of vagal control, reaching significance for rMSSD and log 10 HF, but not for pvRSA, during the last four phases of the hyperglycaemic clamp (hyperglycaemic second phase, GLP-1 first and second phases, and arginine). These associations disappeared when adjusted for age, BMI and insulin sensitivity. Administration of the beta cell secretagogues GLP-1 and arginine led to a significant increase in HR, but this was not paired with a significant reduction in HRV measures. Conclusion/interpretation Experimentally induced hyperinsulinaemia is not correlated with cardiac vagal control or HR when adjusting for age, BMI and insulin sensitivity index. Our findings suggest that exposure to a GLP-1 during hyperglycaemia leads to a small acute increase in HR but not to an acute decrease in cardiac vagal control.
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Introduction
People with obesity and insulin resistance are characterised by decreased heart rate (HR) variability (HRV) compared with healthy controls [1] [2] [3] [4] . Low HRV is a predictor for allcause and cardiac mortality in pre-morbid populations and in various samples of cardiac patients [5] [6] [7] [8] [9] [10] [11] . One mechanism that has been proposed to explain the risk conveyed by low HRV is a decrease in cardiac vagal control, which acts to protect against arrhythmic events [6, 8] . A likely cause of the lower HRV in individuals with insulin resistance, often accompanied by the metabolic syndrome, is their higher levels of insulin. Several studies revealed that an acute increase in insulin decreases HRV and/or increases HR [1, 3, [12] [13] [14] [15] [16] . Most studies focus on sympathetic control over the heart, but there has been relatively little research on the relationship between insulin and vagal control.
To measure cardiac vagal control, various HRV measures are in use. Although all HRV measures are sensitive to changes in vagal activity, HRV in the respiratory frequency range (0.15-0.4 Hz), also called respiratory sinus arrhythmia (RSA), is the preferred measure of cardiac vagal control [17] [18] [19] [20] .
The aim of this study was to test the influence of stepwise increases in serum insulin level on vagal activity. Insulin levels were experimentally manipulated by exogenous insulin administration and administration of secretagoguesglucose, glucagon-like peptide-1 (GLP-1) receptor agonist and arginine-that increase insulin levels endogenously. This was achieved during a euglycaemic-hyperinsulinaemic clamp and a modified hyperglycaemic clamp with GLP-1 and arginine in healthy participants who underwent continuous recording of the ECG and respiratory signals. Because of its clinical application, we have a special interest in the effects that the beta cell secretagogue GLP-1 (in addition to high glucose and insulin levels) has on vagal control in this setting. We hypothesised that higher insulin levels are associated with lower cardiac vagal control, independently of BMI and insulin resistance, and that experimentally induced increases in exogenous or endogenous insulin would decrease cardiac vagal control.
Methods
Participants Between September 2004 and the end of 2006, 154 families were selected from the Netherlands Twin Register to be invited to take part in the Dutch twin-family study 'Genetic influences on beta cell function'. The study protocol was approved by the Medical Ethics Committee of the VU University Medical Center (VUmc) and all participants gave informed consent. Only healthy participants were included, for further inclusion and exclusion criteria see Simonis-Bik et al [21] . Overall, 130 participants (100 twins and 30 siblings) participated in both a euglycaemichyperinsulinaemic clamp and a modified hyperglycaemic clamp. Three participants were excluded from the analysis because their ECG recordings were too noisy during critical parts of the experiment. The remaining 127 participants were 65 women and 62 men aged 20 to 51 years (mean 31.5 years, SD 6.3) with a BMI ranging from 18 to 36 kg/m 2 (mean 24.1 kg/m 2 , SD 3.5).
Clamps The clamp tests were performed on a day that started at 08:00 hours in an academic research unit after a 12 h fast. After weight measurement (balance scale Seca; Schinkel, Nieuwegein, the Netherlands) the participant was confined to bed and an ECG/respiration recording device (Vrije Universiteit Ambulatory Monitoring System [VU-AMS], VU University, Amsterdam, the Netherlands) was attached.
The euglycaemic clamp was performed as in SimonisBik et al [21] and the modified hyperglycaemic clamp was performed as described previously in Simonis-Bik et al and Fritsche et al [21, 22] Fig. 1 as the small black squares just above the timeline). BP measurements were performed in duplicate at fixed intervals (four times in total; represented in Fig. 1 as black squares with a dot in the centre) with an automatic BP meter (Dinamap procare 100; KP Medical, Houten, the Netherlands).
Mean insulin levels were assessed across seven different conditions reflecting different phases of the manipulation of insulin levels (shown as black blocks in Fig. 1 ).
HR and HRV recording The VU-AMS device records the ECG and the thorax impedance (dZ) from six disposable, pre-gelled Ag/AgCl electrodes as described in detail elsewhere [23] [24] [25] . Mean HR and RSA measures were assessed across the seven different conditions, as summarised in Fig. 1 . Fragments of data for which participants were not quietly lying in bed (e.g. to urinate) were removed from further signal analyses.
For each of the seven experimental conditions the interbeat interval of the HR (IBI; ms) was scored using the VU-AMS software suite (VU-DAMS version 2.0, VU University, Amsterdam, the Netherlands).
RSA was assessed in three ways. First, we used the 'peak-valley' method [23, [26] [27] [28] . In this method, RSA is scored from the combined respiration and IBI time series by detecting the shortest IBI during inspiration and the longest IBI during expiration on a breath-to-breath basis [23, 29] . Per breath, estimates of peak-valley RSA (pvRSA) were obtained by subtracting the shortest IBI in the inspirational phase from the longest IBI in the expiration phase. Automatic scoring of pvRSA was checked by visual inspection of the respiratory signal from the entire recording.
Second, we computed the root mean square of successive differences (rMSSD) in IBI using rMSSD IBI=√1/n∑ (IBI i −IBI i−1 ) 2 , in which IBI i −IBI i− 1 is actual IBI−previous IBI. Finally, the high-frequency power (HF) was computed as the power in the 0.15-0.40 Hz band, and the logarithm (log 10 HF) was determined. Mean values for IBI, RMSSD IBI, pvRSA and log 10 HF were computed across the seven different conditions reflecting different phases of the manipulation of insulin levels. Mean IBI was converted to the more conventional notation in HR as HR=60,000/IBI.
For seven participants, RSA values from a single condition were removed as outliers (>4 SDs from the mean).
Statistical analyses
The statistical analyses section is divided into two parts. The first part consists of the crosssectional analyses to test the association between serum insulin level and the RSA measures. In the fasting state and during the six manipulations of insulin level, zeroorder and partial Pearson product moment correlation coefficients (SPSS Statistics version 19, www-01.ibm.com/ software/analytics/spss/products/statistics/) were computed without and with the addition of the covariates age, BMI, and insulin sensitivity index (ISI) [30] . The covariates were selected based on previous findings that HRV measures differ for sex and correlate with age, BMI [31, 32] and ISI [3, 13] .
The second part covers the effects of the manipulation of insulin levels. A mixed-model ANCOVA that accounts for the non-independence of family members (family = random factor) was used to test the effects of the experimental condition (fixed factor) on the RSA measures. The mixed model handles missing data in repeated measurements without removing the entire participant. Six pre-planned post-hoc tests (p bonferroni 0.008) were Achieved power to detect a change of 15% of an SD in these contrasts is 0.95 (n=127, α 0.008) based on an average 0.6 correlation between the repeated measures.
Results
The means of blood insulin levels, BP, HR and the RSA measures are presented for each condition in Table 1 .
Cross-sectional analyses The three measures of cardiac vagal control (HF, rMSSD IBI and pvRSA) were highly intercorrelated in the fasting state (0.73 < r < 0.91), but the correlation was not perfect (i.e. <1.0). Fasting log 10 HF differed significantly between the sexes, with higher log 10 HF (2.7 vs 2.5; p=0.047) for women. The pvRSA, rMSSD IBI and HR were also higher for women (pvRSA 35.7 vs 33.1; rMSSD IBI 40.4 vs 37.7; and HR 67.1 vs 64.2), but this did not reach significance. Table 2 displays correlations between age, BMI and ISI with the three measurements of RSA (rMSSD IBI, log 10 HF and pvRSA), HR and insulin level. Age and BMI correlated significantly with all three measurements, whereas ISI only correlated significantly with HR. The fasting serum insulin level correlated significantly with BMI and ISI. Table 3 shows the correlations of insulin level with HR and the three RSA measures during the entire experimental protocol. The first column depicts the observed correlations. The second column depicts the partial correlations, after correcting for the effects of age, BMI and ISI on insulin levels. In all conditions except the euglycaemic clamp, higher insulin was associated with a higher HR and a lower RSA. In the analyses adjusted for age, BMI and ISI the association between HR and insulin remained partially intact, but the association between RSA measures and insulin disappeared. To explore whether the correlation between insulin level with HR and RSA exists only in normal weight persons, the tests were repeated for participants with a BMI between 20 and 25 kg/m 2 . The results remained the same; there was no significant correlation after adjusting for age and ISI.
Effects of the manipulation of insulin levels Figure 2 displays the mean values for insulin, rMSSD IBI, HF, pvRSA and HR. Insulin, HR, rMSSD IBI and HF showed a significant main effect of the condition. At peak insulin levels the HR increased by 3.9 bpm compared with the fasting level, and the mean rMSSD IBI, HF and pvRSA decreased by 4.5 ms, 69.0 ms 2 (log 10 HF decreased 0.095) and 4.0 ms, respectively. Post-hoc testing on six contrasts revealed that insulin level differences were significant in all tested contrasts. Differences Main effects for conditions were significant in a-c and e (p<0.001 by ANCOVA). Significant contrasts (p bonferroni <0.008) are marked with horizontal lines in (a) and (e) (***p<0.001). There were no significant contrasts for rMSSD, HF or pvRSA. Note that the y-axis in (a) is a logarithmic (log 10 ) scale. F, fasting; EG, euglycaemichyperinsulinaemic; HG, hyperglycaemic; G, GLP-1; Arg, arginine; 1st and 2nd refer to 1st and 2nd phase, respectively; the x-axis applies to all figure parts phase and GLP-1 second phase vs arginine. These posthoc contrasts were not significant for any of the RSA measurements. Some (n = 15) participants felt sick, dizzy or light headed during the arginine condition. To explore whether the effects on HR were caused by nausea, the post-hoc tests with arginine were repeated after controlling for feeling sick. HR was still significantly higher in the arginine condition.
For the six previously mentioned contrasts we computed the changes in insulin and in the HR and RSA measures. Changes in insulin level were not significantly correlated with either the changes in HR or changes in any of the RSA measures (all p values>0.01, corrected for multiple comparisons). Figure 3 displays the means of BP measurements in four conditions. Systolic BP showed a significant main effect of condition. Mean systolic BP was 2.9 mmHg higher in GLP-1 second phase compared with the fasting state.
Discussion
The aim of this study was to learn about the effects of high levels of insulin on cardiac vagal control. We used exogenous insulin infusion and stimulation of endogenous insulin production by different combinations of bolus injections and continued infusion of glucose and other secretagogues to increase levels of insulin.
We found significant associations between insulin levels and HR as well as between insulin levels and various RSA measures that index cardiac vagal control in the fasting state and in various phases of a modified hyperglycaemic clamp. The association of insulin level with resting HR and RSA has been observed previously, amongst others by Schroeder et al [15] in a very large sample (N=9940) that compared healthy individuals with individuals with diabetes and individuals with hyperinsulinaemia. However, when we adjusted for age, BMI and ISI the association between insulin and HR was strongly attenuated and the association between insulin and RSA was no longer significant. This suggests that BMI and ISI, and not insulin level, are the proximal factors influencing HR and cardiac vagal control. This idea was further corroborated by the absence of correlations between the changes in insulin to the changes in HR and RSA during manipulation of insulin levels with glucose and the B cell secretagogues GLP-1 and arginine. The higher HR observed in individuals with high insulin levels in the second phase of the hyperglycaemic clamp and the second phase of the GLP-1 infusion appears to reflect increased cardiac sympathetic control rather than decreased cardiac vagal control.
Although not significant, in the euglycaemic clamp we even see a slight increase in RSA and a slight decrease in HR, paired with a rise in serum insulin level. This is the opposite of our hypothesis and is also in contrast with findings in other studies [3, 13] . These findings could be a coincidence or reflect the different mechanism of insulin increase. The euglycaemic clamp is the only condition in which insulin was increased by exogenous infusion instead of by endogenous production by the beta cell.
Although we find no evidence of an acute effect of increased insulin production on cardiac vagal control, it is important to note that this does not rule out an effect of chronic hyperinsulinaemia on vagal control through its effects on BMI and ISI. If BMI and ISI causally affect cardiac vagal control, the effects of hyperinsulinaemia on body composition and insulin resistance indirectly create a chain of causation between high insulin levels and vagal control. From a clinical perspective, therefore, hyperinsulinaemia may still contribute to impaired vagal control in obese insulin-resistant patients with type 2 diabetes.
A limitation to our study design is that the effects of the secretagogues could not be measured separately. An example is that GLP-1 was tested in conditions of hyperglycaemia, and the true effect of GLP-1 could not be ascertained in these conditions. A second limitation is that we used a within-participant design where different stages of insulin level were induced within each participant in a predefined sequence. Thus, the effect attributed to the single conditions might also reflect the effect of a sequence of (preceding) manipulations. A third limitation is that a control group was not added. The effects of inactively lying on a bed during the day on RSA measurements are unknown and can a b Fig. 3 Means and SEM of all participants (n=127), per condition, for (a) systolic BP and (b) diastolic BP. Error bars show SEM ± 2SEMs. EG, euglycaemic-hyperinsulinaemic; HG, hyperglycaemic; the x-axis applies to both figure parts influence results. Adding a control group who would have received the same infusion of an NaCl solution would have made the results more valid.
During the modified hyperglycaemic clamp a significant increase was observed in HR during infusion of GLP-1 and GLP-1 plus arginine. Although this could reflect the very strong increases in insulin level, our data are more compatible with a true effect of the GLP-1 (in conditions of hyperglycaemia). Of note, the additional arginine more than doubled the insulin level but scarcely increased HR over the level attained during the second phase of GLP-1 infusion only. A cardiac effect of GLP-1 is also in accordance with findings of Griffioen et al [33] that showed that central or peripheral administration of GLP-1 in rats caused increased HR and decreased cardiac vagal modulation. Our study confirms these findings in humans for HR but not for cardiac vagal control, although we also observed the strongest decline in the three RSA measures after the start of GLP-1 infusion. These findings are important in light of the increased use of GLP-1 agonists as a treatment for type 2 diabetes.
We conclude that experimentally induced hyperinsulinaemia is not correlated with HR or cardiac vagal control when adjusted for BMI and ISI. In healthy people, use of a GLP-1 agonist, in conditions of hyperglycaemia, may lead to a small acute rise in HR but does not lead to a significant decrease in cardiac vagal control. Whether longer-term exposure to GLP-1 causes an accumulative reduction in cardiac vagal control in a more vulnerable diabetic patient group is an important area for future investigation.
